Evidence map›Paper›PMID 35954460›Full record

ArticleCancers2022

Effectiveness of Early Radical Cystectomy for High-Risk Non-Muscle Invasive Bladder Cancer.

Elliott Diamant, Mathieu Roumiguié, Alexandre Ingels, Jérôme Parra, Dimitri Vordos, Anne-Sophie Bajeot, Emmanuel Chartier-Kastler, Michel Soulié, Alexandre de la Taille, Morgan Rouprêt and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Elliott DiamantSorbonne Université, Department of Urology, GRC n°5 Predictive Onco-Urology, AP-HP, Pitié-Salpêtrière Hospital, 75013 Paris, France.
Mathieu RoumiguiéDepartment of Urology, CHU-Institut Universitaire du Cancer-Oncopôle, 31000 Toulouse, France.ORCID 0000-0002-2412-146X
Alexandre IngelsDepartment of Urology, University Hospital Henri Mondor, APHP, UPEC, 94000 Créteil, France.
Jérôme ParraSorbonne Université, Department of Urology, GRC n°5 Predictive Onco-Urology, AP-HP, Pitié-Salpêtrière Hospital, 75013 Paris, France.
Dimitri VordosDepartment of Urology, University Hospital Henri Mondor, APHP, UPEC, 94000 Créteil, France.
Anne-Sophie BajeotDepartment of Urology, CHU-Institut Universitaire du Cancer-Oncopôle, 31000 Toulouse, France.
Emmanuel Chartier-KastlerSorbonne Université, Department of Urology, GRC n°5 Predictive Onco-Urology, AP-HP, Pitié-Salpêtrière Hospital, 75013 Paris, France.ORCID 0000-0003-4241-8125
Michel SouliéDepartment of Urology, CHU-Institut Universitaire du Cancer-Oncopôle, 31000 Toulouse, France.
Alexandre de la TailleDepartment of Urology, University Hospital Henri Mondor, APHP, UPEC, 94000 Créteil, France.
Morgan RouprêtSorbonne Université, Department of Urology, GRC n°5 Predictive Onco-Urology, AP-HP, Pitié-Salpêtrière Hospital, 75013 Paris, France.
Thomas SeisenSorbonne Université, Department of Urology, GRC n°5 Predictive Onco-Urology, AP-HP, Pitié-Salpêtrière Hospital, 75013 Paris, France.
Sorbonne Université · FRInstitut universitaire du cancer de Toulouse Oncopole · FRUniversité Paris-Est Créteil · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The purpose of this study is to compare perioperative and oncological outcomes of upfront vs. delayed early radical cystectomy (eRC) for high-risk non-muscle-invasive bladder cancer (HR-NMIBC). Methods: All consecutive HR-NMIBC patients who underwent eRC between 2001 and 2020 were retrospectively included and divided into upfront and delayed groups, according to the receipt or not of BCG. Perioperative outcomes were evaluated and the impact of upfront vs. delayed eRC on pathological upstaging, defined as ≥pT2N0 disease at final pathology, was assessed using multivariable logistic regression. Recurrence-free (RFS), cancer-specific (CSS) and overall survival (OS) were compared between upfront and delayed eRC groups using inverse probability of treatment weighting (IPTW)-adjusted Cox model. Results: Overall, 184 patients received either upfront (n = 87; 47%) or delayed (n = 97; 53%) eRC. No difference was observed in perioperative outcomes between the two treatment groups (all p > 0.05). Pathological upstaging occurred in 55 (30%) patients and upfront eRC was an independent predictor (HR = 2.65; 95% CI = (1.23−5.67); p = 0.012). In the IPTW-adjusted Cox analysis, there was no significant difference between upfront and delayed eRC in terms of RFS (HR = 1.31; 95% CI = (0.72−2.39); p = 0.38), CSS (HR = 1.09; 95% CI = (0.51−2.34); p = 0.82) and OS (HR = 1.19; 95% CI = (0.62−2.78); p = 0.60). Conclusion: our results suggest similar perioperative outcomes between upfront and delayed eRC, with an increased risk of upstaging after upfront eRC that did impact survival, as compared to delayed eRC.

Indexed as

complicationcystectomynon-muscle invasive bladder cancersurvival analysisupstagingurothelial carcinoma

Identifiers

PMID35954460
PMCPMC9367342
OpenAlexW4290085782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.